MacroGenics, Inc.
Status: Publicly traded
Direct answer
MacroGenics, Inc. is publicly traded on NASDAQ under the ticker MGNX.
MacroGenics, Inc. is a U.S.-based biopharmaceutical company specializing in the development and commercialization of antibody-derived treatments primarily aimed at combating cancer. The company's sole approved product is MARGENZA (margetuximab-cmkb). This drug acts as an antagonist to the human epidermal growth factor receptor 2 (HER2) and is prescribed in conjunction with chemotherapy for adult patients suffering...
Can you invest in MacroGenics, Inc.?
Yes. MacroGenics, Inc. is publicly traded on NASDAQ under the ticker MGNX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for MacroGenics, Inc.
Detailed equity research is provided by MarketSnap.